Peptide Receptor Radionuclide Therapy (PRRT)
Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177-Dotatate is a treatment for Neuroendocrine tumors (NET). By administering radioactive lutetium-177 Dotatate, these tumors can be treated with great precision which can improve the overall quality of life. Symptoms often diminish quickly. The treatment is administered t a multidisciplinary team of medical oncologists, nuclear medicine professionals, gastroenterologists, and radiologists. The Netherlands Cancer Institute is the second center in the Netherlands that was accredited for this treatment type. With the addition of PRRT, the shared expert center of the Netherlands Cancer Institute and the UMC Utrecht officially offers all treatment options for patients with NET.